France: InvestEU supports €25 million EIB and Germitec agreement to finance research and development for innovative medical technologies

Germitec and the European Investment Bank (EIB) have signed a €25 million agreement to finance the development and commercialization of new medical products. This agreement was made possible with the support of the InvestEU program, which aims to trigger more than €372 billion in additional investment between 2021 and 2027.

The new products to be financed by this agreement will radically reduce cross-infection risks for patients by providing healthcare professionals with innovative UV-C-based high-level disinfection (HLD) technology and devices. The new technology will radically simplify the lives of healthcare professionals in terms of n safety, time, and liability.

This agreement comes under InvestEU’s research and development policy (new effective and accessible healthcare products, including research, development, innovation, and manufacturing of pharmaceuticals, medical devices, diagnostics, and advanced therapy medicinal products). It will support the achievement of the European Union’s research and development policy objective.

“We are thrilled to benefit from the support of the prestigious European Investment Bank. This financing is a strong recognition of the great potential of our UV-C technology. I am confident we will continue to expand our activities internationally and support healthcare professionals around the world on a daily basis to ensure the safety of their patients during ultrasound examinations,” said CEO of Germitec Vincent Gardès.

“The EIB is pleased to be contributing to the development of Germitec and its innovative technology to prevent cross-infection risks in the disinfection of medical devices. This €25 million in financing demonstrates the European Union’s focus on supporting innovation and promising technologies in the field of healthcare, an area that is vital for people’s well-being,” said EIB Vice-President Ambroise Fayolle.

European Commissioner for Economy Paolo Gentiloni said: “Researching and developing innovative products requires sustained and significant investment. With the help of InvestEU, Europe can retain its position as a world-leader in the development of cutting-edge medical technologies by supporting agreements such as this one.”